Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis

Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement.

El reclamo de los cirujanos en estenosis aórtica de bajo riesgo

However, surgeons argue that these cases fail to consider patients from daily clinical practice, but rather include a population that has been carefully selected for randomized trials.

Patients with non-tricuspid aortic stenosis, with severe coronary artery disease, and requiring concomitant mitral/tricuspid/ascending aorta valve interventions were systematically excluded from such trials.

This study included all consecutive patients with severe aortic stenosis and low surgical risk (Society of Thoracic Surgeons [STS] score of < 4%), who had undergone surgery within a certain period of time (2000-2019). Of 5310 tested patients, a high percentage (40.8%) showed at least one medical condition that would have had them excluded from randomized trials.

The most frequent medical conditions included aortic stenosis in a non-tricuspid valve (27.6%), severe coronary artery disease (5.8%), concomitant mitral disease (5.8%), and ascending aorta disease (10.5%).


Read also: Should Total Occlusion Influence on Revascularization Strategy?


The rates of stroke and 30-day mortality for the whole cohort of low-risk patients were 2.4% and 1.9%, respectively. The global mortality rate was similar to the rate for patients with severe coronary artery disease (2.6%) and ascending aorta disease (2.1%). The global mortality rate was lower than the rate for patients with non-tricuspid disease (0.9%) and higher than the rate for patients with concomitant mitral disease (5.9%).

Conclusion

In a real-world setting, about one half of the patients with severe aortic stenosis and low surgical risk show at least one medical condition that was excluded from randomized trials comparing TAVR and surgical valve replacement.

The results corresponding to this large cohort were similar to or better than those predicted by risk scores in all groups, except for patients with concomitant mitral disease.

These results shall be taken into account when choosing a strategy with patients from daily clinical practice, as well as when designing future trials.

Original Title: Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis Outside Randomized Trials.

Reference: Alberto Alperi et al. J Am Coll Cardiol. 2021 Jan 19;77(2):111-123. doi: 10.1016/j.jacc.2020.10.056.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...